Trial Profile
A Pilot Efficacy and Safety Study of IPX159 for the Treament of Restless Legs Syndrome.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs IPX 159 (Primary)
- Indications Restless legs syndrome
- Focus Therapeutic Use
- 12 May 2011 Status changed from not yet recruiting to completed.
- 15 May 2009 New trial record